Literature DB >> 12052212

Nitroreductase-based GDEPT.

William A Denny1.   

Abstract

Nitroreductases that metabolise aromatic nitro groups to hydroxylamines are attractive as enzymes for GDEPT because of the very large electronic change that this metabolism generates, providing an efficient switch that can be exploited to generate potent cytotoxins. While nitroreductase enzymes are widespread, nearly all the work using these in GDEPT has been with the nfsB gene product of Escherichia coli, an oxygen-insensitive flavin mononucleotide nitroreductase (NTR). Four classes of prodrugs for NTR have been described; dinitroaziridinylbenzamides, dinitrobenzamide mustards, 4-nitrobenzylcarbamates and nitroindolines. While some quinones are excellent substrates for NTR, none have been identified as potential GDEPT prodrugs. The most widely studied prodrug used for GDEPT in conjunction with NTR is the dinitroaziridinylbenzamide CB 1954. This shows high selectivity (>1000-fold) in cell lines transfected with NTR, has potent and long-lasting inhibition of NTR-transfected tumours in mice, and is in Phase I trial in conjunction with virally-delivered NTR enzyme. The related mustard SN 23862 has similar selectivity and superior bystander effects in animal models. Nitrobenzyl carbamates of a variety of cytotoxic amines (including aniline mustards, enediynes, duocarmycin analogues, pyrrolobenzodiazepines and the antitumour antibiotics doxorubicin, actinomycin D and mitomcyin C) are metabolised efficiently by NTR to the hydroxylamines, that fragment to release the amines. Nitroindoline derivatives of duocarmycins also show moderate selectivity for NTR-transfected cell lines in culture.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052212     DOI: 10.2174/1381612023394584

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  10 in total

1.  An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies.

Authors:  Carlos Almeida Ramos; Zahra Asgari; Enli Liu; Eric Yvon; Helen E Heslop; Clio M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Stem Cells       Date:  2010-06       Impact factor: 6.277

2.  In Vivo Chemiluminescent Imaging Agents for Nitroreductase and Tissue Oxygenation.

Authors:  Jian Cao; James Campbell; Li Liu; Ralph P Mason; Alexander R Lippert
Journal:  Anal Chem       Date:  2016-04-15       Impact factor: 6.986

Review 3.  Gene-directed enzyme prodrug therapy.

Authors:  Jin Zhang; Vijay Kale; Mingnan Chen
Journal:  AAPS J       Date:  2014-10-23       Impact factor: 4.009

4.  Nitroreductase-triggered activation of a novel caged fluorescent probe obtained from methylene blue.

Authors:  Jungeun Bae; Louis E McNamara; Manal A Nael; Fakhri Mahdi; Robert J Doerksen; Gene L Bidwell; Nathan I Hammer; Seongbong Jo
Journal:  Chem Commun (Camb)       Date:  2015-08-18       Impact factor: 6.222

5.  CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy.

Authors:  Steve H Thorne; Yoram Barak; Wenchuan Liang; Michael H Bachmann; Jianghong Rao; Christopher H Contag; A Matin
Journal:  Mol Cancer Ther       Date:  2009-02-03       Impact factor: 6.261

6.  Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs.

Authors:  Claudia Karnthaler-Benbakka; Diana Groza; Bettina Koblmüller; Alessio Terenzi; Katharina Holste; Melanie Haider; Dina Baier; Walter Berger; Petra Heffeter; Christian R Kowol; Bernhard K Keppler
Journal:  ChemMedChem       Date:  2016-10-05       Impact factor: 3.466

7.  Synthesis and Biological Evaluation of Lipophilic Nucleoside Analogues as Inhibitors of Aminoacyl-tRNA Synthetases.

Authors:  Manesh Nautiyal; Bharat Gadakh; Steff De Graef; Luping Pang; Masroor Khan; Yi Xun; Jef Rozenski; Arthur Van Aerschot
Journal:  Antibiotics (Basel)       Date:  2019-10-09

8.  Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.

Authors:  Amir Ashoorzadeh; Alexandra M Mowday; Christopher P Guise; Shevan Silva; Matthew R Bull; Maria R Abbattista; Janine N Copp; Elsie M Williams; David F Ackerley; Adam V Patterson; Jeff B Smaill
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-01

9.  Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.

Authors:  Sue Ping Lim; Raman Kumar; Yamini Akkamsetty; Wen Wang; Kristen Ho; Paul M Neilsen; Diego J Walther; Rachel J Suetani; Clive Prestidge; David F Callen
Journal:  BMC Cancer       Date:  2013-03-13       Impact factor: 4.430

10.  Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System.

Authors:  Abigail V Sharrock; Sarah P McManaway; Michelle H Rich; Jeff S Mumm; Ian F Hermans; Moana Tercel; Frederik B Pruijn; David F Ackerley
Journal:  Front Pharmacol       Date:  2021-06-07       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.